Amivantamab: all 33 studies that test it
Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell CarcinomaNot yet recruitingNCT07808359Phase 2
- Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)Not yet recruitingNCT07507188Phase 2
- Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.RecruitingNCT07392658Phase 2
- A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerRecruitingNCT07276399Phase 3
- A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung CancerRecruitingNCT07227025Phase 1/2
- An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.Not yet recruitingNCT06855849Phase 2
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingNCT06750094Phase 3
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerRecruitingNCT06662786Phase 3
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06116682Phase 2
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2
- A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal CancerRecruitingNCT05379595Phase 1/2
- A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)RecruitingNCT03767075Phase 2
- Premedication to Reduce Amivantamab Associated Infusion Related ReactionsActive, not recruitingNCT05663866Phase 2Results posted
- A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaTerminatedNCT05653427Phase 2Results posted
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05388669Phase 3Results posted
- Amivantamab in Adenoid Cystic CarcinomaActive, not recruitingNCT05074940Phase 2Results posted
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureActive, not recruitingNCT04988295Phase 3Results posted
- A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal CancerTerminatedNCT04945733Phase 2Results posted
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsActive, not recruitingNCT04538664Phase 3Results posted
- A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04487080Phase 3Results posted
- 5G-EMERALD: Amivantamab in Malignant Brain TumoursActive, not recruitingNCT06632236Phase 1
- A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung CancerCompletedNCT06532032Phase 1/2
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibActive, not recruitingNCT06120140Phase 2
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerActive, not recruitingNCT06083857Phase 1/2
- A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05908734Phase 1/2
- Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET AlterationsActive, not recruitingNCT05845671Phase 1/2
- A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsActive, not recruitingNCT05801029Phase 2
- Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKIActive, not recruitingNCT05601973Phase 2
- A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05488314Phase 1/2
- Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsCompletedNCT05299125Phase 2
- A Study of Amivantamab in People With Esophagogastric CancerActive, not recruitingNCT05117931Phase 2
- A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04965090Phase 2
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04077463Phase 1